文献速递急性肾损伤慢性肾脏病肾小球疾病

肝病患者中的急性肾损伤

Acute Kidney Injury in Patients with Liver Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-07-28

综述阐述失代偿期肝硬化患者急性肾损伤的多种病因,包括1型肝肾综合征、肾前性氮质血症、急性肾小管损伤、急性间质性肾炎及少见病因,强调需综合诊断并按病因制定治疗方案,如白蛋白扩容、血管收缩剂治疗1型肝肾综合征等。

要点

  • 肝硬化患者急性肾损伤病因多样,1型肝肾综合征是最突出且独特的病因。
  • 诊断需全面评估肾前性氮质血症、急性肾小管损伤、急性间质性肾炎及其他少见病因。
  • 治疗应针对具体病因,1型肝肾综合征以血管收缩剂为主要治疗,肝移植为根本手段。

核心结论

  • 肝硬化患者急性肾损伤需仔细考虑多种潜在致病因素,并实施针对性治疗干预。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 失代偿期肝硬化患者常发生急性肾损伤,且与不良结局相关。
  • 1型肝肾综合征(又称肝肾综合征-急性肾损伤)是肝硬化相关最突出且独特的病因。
  • 肝硬化患者易患肾前性氮质血症、急性肾小管损伤和急性间质性肾炎等传统病因。
  • 其他与慢性肝病相关的少见病因包括腹腔间隔室综合征、与肝硬化心肌病和门肺高压相关的心肾过程以及胆汁性肾病。
  • 某些类型的肾小球肾炎(如IgA肾病或病毒性肝炎相关)也可导致肝硬化患者急性肾损伤。

关键数值与推荐

  • 肾前性急性肾损伤推荐基于白蛋白的容量复苏。
  • 急性肾小管损伤和急性间质性肾炎采用支持治疗、停用致病药物,急性间质性肾炎可能使用糖皮质激素。
  • 除肝移植外,血管收缩剂治疗是1型肝肾综合征的主要治疗。
  • 血管收缩剂反应性由开始使用时机、平均动脉压升高程度和胆汁淤积程度等因素决定。
  • 大量放腹水和利尿剂用于缓解腹腔内高压和肾静脉淤血。

临床怎么用

  • 肝病患者出现急性肾损伤需全面诊断评估以明确病因。
  • 肾前性急性肾损伤推荐基于白蛋白的容量复苏。
  • 急性间质性肾炎可能使用糖皮质激素。
  • 1型肝肾综合征除肝移植外以血管收缩剂为主要治疗。
  • 大量放腹水和利尿剂用于缓解腹腔内高压和肾静脉淤血。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AKI is commonly encountered in patients with decompensated cirrhosis, and it is associated with unfavorable outcomes. Among factors specific to cirrhosis, hepatorenal syndrome type 1, also referred to as hepatorenal syndrome-AKI, is the most salient and unique etiology. Patients with cirrhosis are vulnerable to traditional causes of AKI, such as prerenal azotemia, acute tubular injury, and acute interstitial nephritis. In addition, other less common etiologies of AKI specifically related to chronic liver disease should be considered, including abdominal compartment syndrome, cardiorenal processes linked to cirrhotic cardiomyopathy and portopulmonary hypertension, and cholemic nephropathy. Furthermore, certain types of GN can cause AKI in cirrhosis, such as IgA nephropathy or viral hepatitis related. Therefore, a comprehensive diagnostic approach is needed to evaluate patients with cirrhosis presenting with AKI. Management should be tailored to the specific underlying etiology. Albumin-based volume resuscitation is recommended in prerenal AKI. Acute tubular injury and acute interstitial nephritis are managed with supportive care, withdrawal of the offending agent, and, potentially, corticosteroids in acute interstitial nephritis. Short of liver transplantation, vasoconstrictor therapy is the primary treatment for hepatorenal syndrome type 1. Timing of initiation of vasoconstrictors, the rise in mean arterial pressure, and the degree of cholestasis are among the factors that determine vasoconstrictor responsiveness. Large-volume paracentesis and diuretics are indicated to relieve intra-abdominal hypertension and renal vein congestion. Direct-acting antivirals with or without immunosuppression are used to treat hepatitis B/C-associated GN. In summary, AKI in cirrhosis requires careful consideration of multiple potentially pathogenic factors and the implementation of targeted therapeutic interventions.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cullaro G, Kanduri SR, Velez JCQ, et al. Acute Kidney Injury in Patients with Liver Disease. Clin J Am Soc Nephrol. 2022. PMID: 35902128. doi:10.2215/CJN.03040322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。